Penserra Capital Management LLC Revance Therapeutics, Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$12.46 - $27.87 $20,496 - $45,846	-1,645 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $386 - $498	15 Added 0.92%	1,645 $45,000
Q2 2021 Aug 12, 2021	BUY	$26.8 - $31.84 $536 - $636	20 Added 1.24%	1,630 $48,000
Q1 2021 May 13, 2021	BUY	$24.03 - $29.97 $2,042 - $2,547	85 Added 5.57%	1,610 $44,000
Q4 2020 Feb 12, 2021	BUY	$23.41 - $28.34 $22,497 - $27,234	961 Added 170.39%	1,525 $43,000
Q3 2020 Nov 13, 2020	BUY	$23.23 - $34.3 $13,101 - $19,345	564 New	564 $14,000

233

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.